CCND1 and breast cancer: Upon 16-day treatment with BI01002494 no specific increase in proliferation (cyclin D1/2, PCNA) or invadopodia (MMP14, PARP) markers is observed in either DU4475 or MDA-MB-468 (Figure 3A) breast cancer cell lines.